Trial Profile

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alectinib (Primary) ; Brigatinib (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary) ; Ensartinib (Primary) ; Lorlatinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
Indications Carcinoma; Non-small cell lung cancer
Focus Biomarker; Therapeutic Use
Acronyms NCI-NRG ALK Protocol

Most Recent Events

23 Apr 2026 Status changed from active, no longer recruiting to discontinued.
07 Apr 2026 Planned End Date changed from 10 Feb 2027 to 18 Mar 2027.
19 Mar 2026 Planned End Date changed from 2 Dec 2026 to 10 Feb 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com